Eli Lilly and Abbisko Announce Drug Development Collaboration

Eli Lilly has entered into a new strategic research collaboration with Abbisko Therapeutics to leverage its early-stage drug discovery platform for multiple targets, deepening a partnership that began in 2022. This move highlights a broader industry trend of major pharmaceutical firms utilizing external R&D ecosystems to bolster their pipelines alongside significant technological shifts in manufacturing. The collaboration comes as the sector also navigates complex economic pressures from the rapidly expanding 340B Drug Pricing Program and advancements in 3D printing production.

Eli Lilly’s new agreement with Abbisko Therapeutics leverages Abbisko’s early-stage drug discovery platform to advance specific targets selected by Lilly. Under the terms of the collaboration, Lilly will provide upfront payments, while Abbisko remains eligible for tiered milestone payments based on development, regulatory, and commercial progress. This deal follows other recent strategic moves by Lilly to access external discovery platforms, including the acquisition of Centessa Pharmaceuticals for sleep-wake disorder treatments and the acquisition of Ajax Therapeutics to gain a lead oncology asset targeting myelofibrosis and polycythemia vera.

Technological innovation in the sector is further exemplified by Aprecia Pharmaceuticals, which is employing 3D printing for additive manufacturing to accelerate drug production. Kyle Smith, president and COO of Aprecia, explained that their platform monitors up to 22 real-time data points per tablet, utilizing NIR probes and laser cameras to ensure quality during the layer-by-layer build process. This method allows for immediate quality monitoring and rapid iteration, bypassing the traditional delays of laboratory-based batch analysis and providing a high level of confidence in the design space before manufacturing even begins.

On the market access front, the 340B Drug Pricing Program has grown into a dominant economic force, reaching a record $81.4 billion in discounted purchases in 2024, a 23% increase over the previous year. Industry advisor Partha Anbil notes that 340B is now the second-largest federal drug program when measured at list prices, driven by hospital vertical integration and an explosion in contract pharmacy arrangements. This growth has sparked ongoing legal battles over manufacturer restrictions and rebate models, making the program a central concern for pharmaceutical manufacturers regarding gross-to-net revenue management and pricing strategy as they navigate a fragmented state-by-state regulatory landscape.